Advances in systolic heart failure by Yuzefpolskaya, Melana et al.
Advances in systolic heart failure
Melana Yuzefpolskaya, Catherine Weinberg and Marrick Kukin*
Address: Division of Cardiology, Department of Medicine, St Luke’s Roosevelt Hospital, Columbia University College of Physicians and Surgeons,
425, 425 West 59
th Street, New York, NY 10019, USA
*Corresponding author: Marrick Kukin (mkukin@chpnet.org)
F1000 Medicine Reports 2010, 2:31 (doi:10.3410/M2-31)
The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/medicine/content/2/31
Abstract
Heart failure due to systolic dysfunction has enormous global impact. Medical management based on
an understanding of the pathophysiology of the disease as well as its neurohormonal mechanisms has
greatly advanced over the past 25 years. Below is a review of recent and emerging data on
epidemiology and diagnosis of heart failure due to systolic dysfunction and the current and future
management techniques to ameliorate this disease. At the end, we will highlight three significant trials
in the field in 2009 that will impact heart failure care: STICH, MADIT-CRT, and HeartMate II.
Introduction and context
Heart failure (HF) is a major public health problem.
Incidence, prevalence, and risk have been found to be
high in both Europe and the US [1,2]. The Rotterdam
study [1] found that a man and a woman at age 55 have,
respectively, a 33.0% and 28.5% chance of developing
HF during their remaining lifetime, whereas the Fra-
mingham Heart Study reported lifetime risks at age 50 of
20.9% for men and 20.5% for women. The Rotterdam
study further showed that the prevalence of HF increased
with age; in 1998, 0.9% of subjects 55-64 years old had
HF compared with 17.4% of those 85 years old or older.
Approximately 5.7 million Americans have been diag-
nosed with the disease [3], and each year an additional
550,000 patients are diagnosed for the first time [4].
This increasing clinical burden is expected to be matched
with an increasing financial burden. By means of a
prevalence-based approach, the economic burden of HF
in the UK was estimated to be £905.3 million in 2000, a
26% increase over 1995 estimates and equivalent to
1.91% of the total National Health Service expenditure
[5]. It is estimated that, in 2009, over $37.2 billion was
spent on costs of HF in the US [3]. Medicare expends
more dollars for the diagnosis and treatment of HF than
for any other diagnosis, as HF is the most frequent
Medicare diagnosis-related group [4]. Hospital
discharges for HF increased by 171% from 1996 to
2006 [1]. In 2005, the number of ‘total mention’ deaths
from HF in the US was 292,000, which is higher than in
1995 (287,000) [3]. HF is declared on 1 in 8 death
certificates [1]. Although considerable advances have
been made in the management of HF over the past few
decades, HF remains a major public health issue with
high prevalence and poor outcomes.
An understanding of the pathophysiology and natural
history ofHF underpinsthe therapeutic approachesused to
achieve the goals of treatment, which are to relieve
symptoms, to avoid hospital admission, and to prolong
life. On the basis of a large number of randomized
controlled trials, drugs are the mainstay of treatment for all
patients with HF and reduced left ventricular systolic
function.Devicetherapyandtransplantsurgeryhavecarved
o u tar e s p e c t a b l ep l a c ei nt h ef i e l do v e rt h ep a s td e c a d e .
Diuretics are essential for relief of dyspnea and signs of
sodium and water retention; they are needed in virtually
all patients with symptomatic HF. These are best used
flexibly and in the minimum dose needed to maintain
euvolemia and avoid electrolyte disorders (hypokalemia
and hyponatremia), gout, and renal dysfunction. In
advanced HF, high doses of loop diuretics and thiazide
or thiazide-like diuretic (metolazone) might be needed
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diuretics, no evidence exists to date to show that these
agents prolong survival, and their use could activate key
neurohormonal systems such as the renin angiotensin
aldosterone system (RAAS) [6,7].
RAAS is important for progression of the HF disease
process; conversely, attenuation of this system has
yielded considerable benefit in the management of
systolic HF. Angiotensin-converting enzyme inhibitors
(ACEIs), by reducing the production of angiotensin II
and possibly by blocking the degradation of bradykinin,
exert many biological effects that lead to improvement
in symptoms, fewer admissions to the hospital, and
prolonged survival in HF; as a consequence, they are
recommended for all patients with systolic dysfunction.
Reduced mortality was also noted with ACE inhibition
in people with recent myocardial infarction and left-
ventricular systolic dysfunction, but without HF symp-
toms [8,9]. The main causes of intolerance are cough,
symptomatic hypotension, and renal dysfunction, which
are exacerbated by overdiuresis and nonsteroidal anti-
inflammatory drugs.
Angiotensin receptor blockers (ARBs) seem to be a
reasonable alternative for patients unable to tolerate ACE
inhibition secondary to cough [10]. However, the use of
ACE inhibition in addition to ARBs remains uncertain.
Several studies that looked at the combination of ACEIs
and ARBs in HF patients are worth mentioning. The
Valsartan Heart Failure Trial (Val-HeFT) included
patients with a left ventricular ejection fraction (LVEF)
of less than 40% and New York Heart Association
(NYHA) class II-IV; 92% were on ACEIs and 35% were
on beta blockers [11]. All patients were randomly
assigned to valsartan versus placebo. Overall mortality
was similar in the two groups. Rates of death from any
cause during the entire trial were 19.7% in the valsartan
group and 19.4% in the placebo group (P = 0.8).
Combined endpoint of death from any cause, hospita-
lization for HF, cardiac arrest with resuscitation, and
intravenous therapy was statistically significant (P =
0.009); however, it was driven mainly by a decline in
hospitalization rate for HF (13.8% in the valsartan group
and 18.2% in the placebo). Patients were further
subdivided into subgroups based on their background
therapy (ACEIs and beta blockers). Among those who
were receiving both drugs at baseline, valsartan had an
adverse effect on mortality (P =0 . 0 0 9 )a n dw a s
associated with a trend toward an increase in combined
endpoints of mortality and morbidity (P = 0.1) [11]. The
Candesartan in Heart Failure – Assessment of Reduction
in Mortality and Morbidity trial (CHARM-Added) was
the only study that showed a reduction in cardiovascular
mortality (absolute risk reduction [ARR] of 3.6%) for
combination therapy; it also showed reduced hospitali-
zation for HF (ARR of 4%) [12]. However, the all-cause
mortality was not different between the groups. Given
the available data, it is safe to conclude that combination
treatment in HF patients should be used with caution.
Both Val-HeFT and CHARM-Alternative confirm that
ARBs are appropriate substitutes for ACEIs when cough is
the reason for intolerance [10,11].
By contrast, use of the aldosterone receptor antagonist
spironolactone in patients with advanced disease (class
III or IV systolic HF) yielded clear-cut survival benefits
additional to background ACE inhibition, although only
a few people were receiving beta blockers [13]. Further-
more, the selective aldosterone receptor antagonist
eplerenone was of benefit in individuals with systolic
HF early after myocardial infarction [14]. Careful
attention to the development of hyperkalemia during
initiation is an essential safety measure when using
aldosterone antagonists. Furthermore, potassium sup-
plements should be discontinued until the potassium
levels reach equilibrium after several months of usage.
Beta blockers are a cornerstone of systolic HF manage-
ment. Chronic activation of the sympathetic nervous
system – the cardiac effects of which are attenuated by
beta blockers – has a key role in HF disease progression,
including fibrosis, necrosis, apoptosis, and arrythmogen-
esis. The beneficial effects of beta blockers have largely
been studied as additional to background ACE inhibi-
tion, and therefore both are judged to be mandatory
treatment. These effects have been shown with bisopro-
lol, carvedilol, and extended-release metoprolol in
patients with stable systolic HF across a broad range of
disease severities.
Beta blockers in HF patients should be initiated at low
doses and gradually up-titrated to the target dosages
proven effective in the major mortality trials (carvedilol
25 mg twice daily, bisoprolol 10 mg daily, or metoprolol
succinate 200 mg daily) [15-17]. Researchers in the
CardiacInsufficiencyBisoprololStudyIII(CIBISIII)raised
the hypothesis that the order of initiation of ACEIs and
betablockersmightnotbevitaltooutcomesprovidedthat
eventually the patient is receiving appropriate doses of
both classes of drug in a timely manner [18].
The combination of hydralazine and isosorbide dini-
trate was the first treatment shown to improve survival
in HF, but a subsequent study showed that it was less
effective than an ACEI in direct comparisons. A strategy
of adding a vasodilator combination to conventional
treatment, including an ACEI, a beta blocker, and
Page 2 of 7
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:31 http://f1000.com/reports/medicine/content/2/31spironolactone, was shown to reduce mortality and
admissions to hospital for HF in African-American
patients, although this conclusion was based on a small
number of events [19].
Recent advances
Surgical Treatment for Ischemic Heart Failure (STICH)
trial
Although cardiac transplantation remains the ultimate
surgical strategy for HF, the poor availability of suitable
donor organs renders this option epidemiologically
insignificant. Other surgical approaches to HF include
revascularization for ischemic HF, mitral valve repair to
address functional mitral regurgitation associated with
pathological ventricular remodeling, and surgical recon-
struction of the size and shape of the failing left ventricle
(LV) to render it more effective to pump. With the
exception of the recently published Surgical Treatment
for Ischemic Heart Failure (STICH) trial [20], most of
these surgical techniques have not been adequately
tested. The STICH trial, funded by the National Heart,
Lung, and Blood Institute, is a multicenter international
randomized trial addressing two specific primary
hypotheses: (a) coronary artery bypass grafting (CABG)
with intensive medical therapy improves long-term
survival compared with survival with medical therapy
alone, and (b) in patients with anterior left ventricular
dysfunction, surgical ventricular reconstruction to a
more normal left ventricular size plus CABG improves
survival free of subsequent hospitalization for cardiac
cause when compared with CABG alone. Subjects
meeting the broad inclusion criteria of coronary artery
disease (CAD) amenable to CABG with an LVEF of 0.35
or less without a specific exclusion were segregated into
three strata, depending on investigator-determined suit-
ability for continued medical therapy alone and eligi-
bility for surgical ventricular restoration (SVR). Eligibility
for medical therapy alone was defined by the investigator
but generally excluded patients with intraluminal left
main coronary artery stenosis of 50% or more or severe
disabling angina (Canadian Cardiovascular Society
[CCS] class III) unresponsive to nonsurgical interven-
tions. Eligibility for SVR is defined as dominant LV
akinesia or dyskinesia amenable to SVR. Stratum A
subjects are defined as suitable for medical therapy with
or without CABG, and consenting patients are randomly
assigned in a 1:1 ratio to medical therapy alone or
medical therapy with CABG. Stratum B subjects, defined
as eligible for all three treatment options, are randomly
assigned in a 1:1:1 ratio to medical therapy alone,
medical therapy with CABG, or medical therapy with
CABG and SVR. Subjects eligible for CABG and SVR are
randomly assigned in a 1:1 ratio to stratum C to either
CABG or CABG with SVR.
Enrollment is now complete in both STICH hypotheses.
The primary outcome of the second hypothesis was
recently reported. This study included 1000 patients
(from96clinicalcenters)whowererandomlyassignedto
undergo either CABG alone (499 patients) or CABG with
SVR (501 patients). The patients were closely matched in
demographic and clinical characteristics. The median age
was 62 years, and 147 of the 1000 patients were women.
The median left ventricular function was 28%, and the
median left ventricular end systolic volume index
(LVESVi) was 82 mL per square meter of body surface
area. Multivessel CAD was present in 64% of patients in
each group. Although standard HF treatment was
recorded at baseline and was encouraged throughout
the trial, no information about the rates of its use over
time is provided. All patients were followed up for
48 months (minimum of 30 months). The two strategies
were equally successful in improvement of patients’
symptoms, with an average improvement in CCS class of
1.7 classes (P = 0.84) and an average of 1 NYHA class (P =
0.7). Equivalent improvement in the 6-minute walk test,
obtained at baseline and 4-month follow-up, was
demonstrated between the two groups (48 m among
patients who were assigned to CABG and 52 m among
patients assigned to CABG and SVR; P = 0.8).
There was a greater reduction in LVESVi with combined
procedure (16 mL per square meter of body surface area)
when compared with CABG alone (5 mL per square
meter of body surface area).
The primary outcome of death from any causes or
hospitalization for cardiac causes was the same in CABG
alone (59%) when compared with CABG with SVR
(58%) (Figure 1). Death occurring within 30 days after
the procedure did not differ significantly between the
two study groups. Subgroup analysis showed no
individual variables interacting significantly with the
study group assignment.
The first STICH trial hypothesis is addressing an
important question of revascularization of patients
with CAD and LV systolic dysfunction. Although specific
clinical problems in this population, such as severe
angina, are used to decide on revascularization strategies,
the vast majority of patients with ischemic cardiomyo-
pathy (ICM) have limited or no angina and fall into a
gray zone where clear evidence for adding CABG to
optimal medical therapy is either absent or outdated.
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with Cardiac Resynchronization Therapy (MADIT-CRT)
Recent guidelines recommend cardiac resynchronization
therapy (CRT) in patients with an LVEF of less than 35%,
NYHA class III-IV symptoms, and a QRS duration of
greater than 0.12 seconds [4]. This represents a subgroup
of HF patients with abnormal cardiac conduction and
possible ventricular dyssynchronous contraction [4].
Dyssynchronous contraction results in suboptimal
ventricular filling, reduced LV dP/dt (rate of rise in LV
pressure), prolonged duration and severity of mitral
regurgitation, and paradoxical septal wall motion [4].
Studies have shown that HF patients with ventricular
dyssynchrony have an increase in mortality [4]. CRT is a
biventricular pacemaker device that electrically paces the
right and left ventricles in a synchronized mode and thus
may improve ventricular contraction and diminish
secondary mitral regurgitation [4]. CRT in conjunction
with optimal medical therapy has been shown to
significantly improve quality of life, functional class,
exercise capacity and distance, and ejection fraction (EF),
as well as reduce HF hospitalizations by 32% and all-
cause mortality by 25% (in a meta-analysis) [4]. It was
unknown whether these devices would be beneficial in
asymptomatic or mildly symptomatic patients.
MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial with Cardiac Resynchronization
Therapy) investigated whether CRT-D (CRT + implan-
table cardioverter defibrillator [ICD] device) would
reduce all-cause mortality and HF events (need for
intravenous diuretic therapy as an outpatient or aug-
mented HF regimen during hospitalization) in patients
who qualify for ICD but are NYHA class I or II [21].
Inclusion criteria were age of more than 21 years, an
LVEF of not more than 30%, stable optimal medical
therapy, a QRS of at least 130 ms, normal sinus rhythm,
and NYHA class I or II (ICM) or class II (nonischemic
cardiomyopathy). In a 3:2 ratio, 1820 patients were
randomly assigned to either CRT-D (1089) or ICD (731)
alone. ICD devices were optimized to minimize right
ventricular pacing. Successful device implantation
occurred in 98.4% of patients, and 95.4% were in their
originally assigned arm. The groups were well matched at
baseline, and for the entire study group, ICM occurred in
about 55% of patients, approximately 10% had NYHA
class III/IV symptoms more than 3 months prior to
enrollment, mean LVEF was 24%, with a mean 6-minute
walk distance of about 361 ms, 70% had left bundle
branch block, and 64% had a QRS width of at least
150 ms. Medical therapy was optimized with 93%
receiving beta blockers, 97% ACEIs or ARBs, 31%
aldosterone antagonist, 74% diuretics, 67% statin, and
7% amiodarone.
The trial was terminated early after a mean follow-up of
2.4 years because of a significant difference in the
combined primary endpoint. Death or nonfatal HF
events were 17.2% for CRT-D versus 25.3% for ICD
(hazard ratio 0.66, 95% confidence interval [CI] 0.52-
0.84; P = 0.001) (Figure 2). Reduced HF events (13.9%
versus 22.8%, P <0.001) drove the primary endpoint to
significance, with no difference in all-cause mortality
Figure 1. Kaplan-Meier estimates of outcomes [20]
(A) The probability of the primary outcome (death from any cause or
hospitalization for cardiac causes), which did not differ significantly between
the two groups. The primary outcome occurred in 292 patients (59%)
assigned to undergo coronary artery bypass grafting (CABG) alone and in
289 patients (58%) assigned to undergo CABG with surgical ventricular
reconstruction (SVR) (hazard ratio 0.99, 95% confidence interval [CI] 0.84
-1.17). (B)The probability of death from any cause, which occurred in
141 patients (28%) assigned to undergo CABG and in 138 patients (28%)
assigned to undergo CABG with SVR (hazard ratio 1.00, 95% CI 0.79-
1.26). Reproduced with permission from [20]. Copyright © 2009,
Massachusetts Medical Society. All rights reserved.
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women and patients with a QRS duration of 150 ms or
more showed a greater benefit. Improvement of LVEF
occurred compared with baseline in the CRT-D arm
(0.11 versus 0.03, P <0.001) as measured by echocar-
diography in a subgroup of patients. LVESV and LVEDV
(left ventricular end diastolic volume) decreased sig-
nificantly compared with baseline in the CRT-D arm
(57 versus 18 mL and 52 versus 15 mL, respectively;
P <0.001). More frequent device-related adverse out-
comes occurred in the CRT-D arm compared with the
ICD arm in the 30 days after implantation [21].
Among criticisms of the study are that approximately
10% of patients qualified for CRT with NYHA class III
or IV more than 3 months prior to random assignment.
Also, patients were assessed by investigators who were
not blinded to the patients’ device and thus there was a
possible bias toward the CRT-D arm [22]. However, there
was a blinded independent clinical events adjudication
committee.
MADIT-CRT results reveal that CRT-D reduced the
primary combined endpoint of death or HF events as
compared with ICD alone with optimal medical
management in NYHA class I and II patients, driven
largely by a reduction in HF events [21]. While these
effects may have been exaggerated due to the early
termination of follow-up, it is also likely that a longer
follow-up in these NYHA I/II patients would have shown
a beneficial effect on mortality. As a result of this and
other studies, device therapy has begun to play an even
greater role in the management of HF patients.
Continuous-flow left ventricular assist device
Despite current treatments with optimal medical and
device therapy including CRT, a number of HF patients
will proceed to refractory HF. Continuous intravenous
inotropic assists in the short term only, and transplants
are offered to a very small percentage of HF patients.
Thus, more permanent solutions with mechanical
circulatory support devices such as left ventricular assist
devices (LVADs) are being evaluated. In 2002, the
landmark REMATCH (Randomized Evaluation of
Mechanical Assistance for the Treatment of Congestive
Heart Failure) trial was the first to randomly assign
nontransplantable end-stage HF patients to optimal
medical management or LVAD plus optimal medical
management [23]. A 48% risk reduction in death from
any cause was found in the LVAD group as compared
with medical therapy alone [23]. One-year survival rate
was 52% with LVAD and 23% at 2 years versus 25% in
the medically treated patients at 1 year and only 8% at
2 years [23].
The older pulsatile-flow LVAD used in REMATCH was
compared with the new continuous-flow HeartMate II
device in the Advanced Heart Failure Treated with
Continuous-Flow Left Ventricular Assist Device (‘Heart-
Mate II’) trial. The continuous-flow device has fewer
moving parts, is much smaller, and has less mechanical
breakdown than the pulsatile-flow LVAD. Patients with
advanced HF (EF of less than 25%, peak oxygen
consumption of less than 14 mL/kg per minute or less
than 50% of the predicted value, and NYHA class IIIB or
IV symptoms for at least 45 of the 60 days before
enrollment), refractory to optimal medical management
(dependence on an intra-aortic balloon pump for 7 days
or inotropes for at least 14 days before enrollment), and
ineligible for transplantation were evaluated [24]. Ran-
dom assignment occurred in a 2:1 ratio to undergo
implantation of a continuous-flow device, HeartMate II
(134 patients), or the currently approved pulsatile-flow
device HeartMate XVE (66 patients). The primary
composite endpoint was survival free from disabling
stroke and reoperation to repair or replace the device at
2 years. Secondary endpoints were survival, frequency of
adverse events, quality of life, and functional capacity.
The two treatment groups had similar preoperative
characteristics, including a median age of 64 years
(range of 26-81) and a mean LVEF of 17%, and almost
80% had received intravenous inotropic agents, more
Figure 2. Kaplan-Meier estimates of the probability of survival
free of heart failure [21]
There was a significant difference in the estimate of survival free of heart
failure between the group that received cardiac resynchronization therapy
plus an implantable cardioverter defibrillator (CRT-ICD) and the group that
received an ICD only (unadjusted P <0.001 by the log-rank test).
Reproduced with permission from [21]. Copyright © 2009, Massachusetts
Medical Society. All rights reserved.
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pump, and greater than 60% failed CRT. The primary
composite endpoint occurred more frequently in
patients with continuous-flow devices (62 of 134
[46%]) than with pulsatile-flow devices (7 of 66
[11%]; P<0.001). Patients with continuous-flow devices
had greater actuarial survival rates at 2 years (58% versus
24%; P = 0.008). Estimated 1- and 2-year survival rates
were 68% (95% CI 60-76%) and 58% (95% CI 49-67%),
respectively, with the continuous-flow device and 55%
(95% CI 42-69%) and 24% (95% CI 1-46%) with the
pulsatile-flow device. The better durability of the Heart-
Mate II continuous-flow device was the primary deter-
minant of the significant positive endpoint. One-third of
patients with pulsatile-flow LVAD required pump
replacements, one required urgent transplantation, and
three required device explantation. About 10% of
patients with continuous-flow LVAD required pump
replacements due to breakage of the percutaneous lead,
pump thrombosis, or outflow elbow disconnection.
Major adverse events were significantly reduced in
patients with a continuous-flow LVAD, including device-
and non-device-related infection, right HF, respiratory
failure, renal failure, and cardiac arrhythmia. The
incidence of stroke did not differ significantly between
groups. There was a significant improvement in quality
of life and functional capacity in both groups.
Limitations of the study include the potential bias
despite random assignment of the devices because both
patient and physician were aware that the device was
being implanted [25]. The study failed to report the
number of patients screened. It also did not report the
postoperative mortality [25].
Overall, the study found that continuous-flow LVAD in
patients with advanced HF significantly improved the
probability of survival-free device failure at 2 years as
compared with a pulsatile device [24]. Most importantly,
the study demonstrated that the survival of patients with
a continuous-flow device is twice that of the REMATCH
trial pulsatile-flow group at 2 years, thus illustrating that
newer technology and improved medical treatment have
enhanced the survival of refractory HF patients in the
past decade [24].
Implications for clinical practice
Medical therapy with optimal doses of ACEI and beta
blocker based on patient tolerability and clinical trial
evidence is essential for HF therapy. The judicious use of
diuretics, in conjunction with a low sodium diet, helps to
manage the volume overload of this condition. Patients
must follow appropriate lifestyle recommendations: no
smoking, moderate exercise, avoidance of nonsteroidal
anti-inflammatory drugs, and avoidance of alcohol. The
careful addition of aldosterone antagonists or ARBS (or
both) can improve outcomes. Finally, the appropriate
use of bypass surgery and devices (ICDs, CRT-D, and
LVADs) can beneficially impact morbidity and mortality
for HF patients.
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